Contemporary Post-Discharge Management in Heart Failure At Home

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to assess whether patients with acute heart failure (HF) can achieve the same level of HF-therapies by digital follow-up at home as compared to hospital visits according to the STRONG-HF strategy. Patients admitted to hospital with acute HF will be enrolled and randomized to either follow-up at the hospital out-patient clinic or digital follow-up at home.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Hospital admission within the 72 hours prior to screening for acute HF.

• NT-proBNP \> 1,500 pg/mL measured during the hospitalization

• Systolic blood pressure ≥ 100 mmHg and of heart rate ≥ 60 bpm within 24 hours before randomization

• Serum potassium ≤ 5.0 mEq/L (mmol/L).

• ≤ ½ the optimal dose of ACEi/ARB/ARNi or beta-blocker or MRA.

• Written informed consent to participate in the study.

Locations
Other Locations
Norway
Drammen Hospital, Vestre Viken HF
RECRUITING
Drammen
Akershus University Hospital
RECRUITING
Lørenskog
Contact Information
Primary
Peder L Myhre, MD, PhD
p.l.myhre@medisin.uio.no
+47 93025644
Backup
Henrik Schirmer, MD, PhD
henrik.schirmer@medisin.uio.no
Time Frame
Start Date: 2024-10-01
Estimated Completion Date: 2028-04-01
Participants
Target number of participants: 450
Treatments
Experimental: Home care
Follow-up and management of HF medications at home visits after 1, 2, 3 and 6 weeks performed by telecommunication led by HF nurses in close communication with physician at the institution. Around week 2 a single visit to the primary care physician's office is required.
Active_comparator: Hospital care
Follow-up and management of HF medications provided by specialists at the participating institutions' outpatient clinics after 1, 2, 3 and 6 weeks. (Same as the high-intensity arm in STRONG-HF)
Related Therapeutic Areas
Sponsors
Collaborators: Oslo University Hospital, Drammen sykehus
Leads: University Hospital, Akershus

This content was sourced from clinicaltrials.gov